Given the common overexpression of AXL in sarcomas as compared to other solid tumors and considering its increased expression in cancers with resistance to chemotherapy or radiotherapy, as well as its association with epithelial-to-mesenchymal transition in solid tumors [14,15,16,17], AXL is a rational candidate for targeted treatment approaches in mesenchymal malignancies. Here, AXL is linked to sarcoma.